Source: https://www.global-regulation.com/law/australia/217549/national-health-%2528efficient-funding-of-chemotherapy%2529-special-arrangement-amendment-instrument-2015-%2528pb-31-of-2015%2529.html
Timestamp: 2018-08-15 05:56:09
Document Index: 708751221

Matched Legal Cases: ['art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 2']

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2015 (PB 31 of 2015) (Australia)
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2015 (PB 31 of 2015)
Link to law: https://www.comlaw.gov.au/Details/F2015L00434
PB 31 of 2015
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 20151
(1) This instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2015.
(2) This instrument may also be cited as PB 31 of 2015.
[1] Section 3 (definition of authority prescription)
(a) in accordance with regulation 13 of the Regulations as modified by this Special Arrangement; or
[2] Section 3
Insert the definition:
[3] Section 3 (definition of infusion medication chart)
[4] Section 3 (definition of medication chart prescription)
[5] Section 3 (definition of non-approved public hospital authority)
[6] Section 3
[7] Section 3 (definition of Streamlined Authority Code)
[8] Section 3 (notes under definition of supplier and definition of under co-payment data)
Repeal the notes under these definitions.
[9] Section 3 (after definition under co-payment data)
Omit the note, and substitute:
[10] Subsection 9(2)
After “infusion medication chart” insert “prescription”.
[11] Subsection 10(1)
[12] Subsection 10(2)
Omit “or medication chart”.
[13] Subsection 11(2)
[14] Subsection 12(1)
[15] Subsection 12(2)
[16] Paragraph 14(1)(b)
Repeal this paragraph , substitute:
(b) preparing an infusion medication chart prescription for an infusion that includes the chemotherapy drug in the chemotherapy pharmaceutical benefit, in accordance with regulation 19AA of the Regulations as modified by section 16.
[17] Subsections 14(2), (3) and (4)
Repeals these subsections, substitute:
(4) An infusion prescription written in accordance with section 15 or an infusion medication chart prescription written in accordance with section 16 is taken to be a duly written prescription for regulation 19 or 19AA of the Regulations.
(5) Paragraph 19(2)(a) of the Regulations does not apply to an infusion prescription.
Note: Regulation 19AA does not prohibit same day prescribing for infusion medication chart prescriptions.
[18] Section 15
15 Information to be included in infusion prescription, other than infusion medication chart prescriptions.
[19] Paragraphs 15(2)(c) and (d)
[20] Section 16
(1) For paragraph 14(1)(b) this section modifies the requirements of regulation 19AA of the Regulations.
[21] Paragraphs 17(1)(a) and (b)
the prescription must be authorised in accordance with the procedures set out in regulation 13 of the Regulations as modified by subsection (2).
[22] Paragraphs 17(3)(a) and (b)
the prescription must be authorised in accordance with the procedures set out in regulation 13 of the Regulations as modified by subsection (4).
[23] Subsection 18(1)
[24] Subsection 18(3)
[25] Paragraph 19(1)(b)
(b) writing a medication chart prescription for the related pharmaceutical benefit in accordance with regulation 19AA of the Regulations.
[26] Subsection 19(2)
[27] Section 20
[28] Section 21
[29] Subsection 22(1)
[30] Subsection 22(2)
Omit “or medication chart”, substitute “(including a medication chart prescription)”.
[31] Subsection 22(3)
[32] Subsection 22(4)
[33] Subsection 22(5)
[34] Section 23
[35] Section 24
[36] Section 25
[37] Section 26
[38] Section 27
[39] Section 28
[40] Section 29
[41] Paragraph 31(1)(c)
After “hospital;” insert “or”.
[42] Subsection 31(3)
[43] Subsection 33(1)
[44] Subsection 33(2)
[45] Subsection 33(3)
[46] Subsection 33(6) note
In the note after “each chemotherapy drug and” insert “for an infusion prescription”.
[47] Subsection 33(7)
[48] Subsection 33(7) note
Omit the note.
[49] Subsection 34(3)
Omit “infusion” insert “infusion for an infusion prescription”.
[50] After subsection 34(3)
Note: Regulations 24 and 26A already do not apply to infusion medication chart prescriptions.
[51] Subsection 34(5)
Repeal the subsection and subheading.
[52] Section 35
[53] Subsection 36(2)
[54] Section 38
[55] Paragraph 39(c)(iii)
[56] Paragraph 39(d) (note)
[57] Section 40
[58] Section 44
[59] Subsection 52(1)
After “to an eligible” insert “public hospital”.
[60] Section 56
[61] Subsection 57(1)
Omit “eligible patient” insert “eligible public hospital patient”.
[62] Subsection 57(2)
[63] Subsection 57(3)
[64] Paragraph 59(c)
[65] Section 60
before 1 April 2017, by following the requirements for prescribing from an infusion medication chart or medication chart in the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 as in force immediately before 1 April 2015.
(4) However, this section does not apply if the participating hospital authority referred to in subsection (2) is a listed approved hospital under regulation 59 of the Regulations and supplying from infusion medication chart prescriptions under this Special Arrangement.
[66] Schedule 1 Part 1 entry for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 20 mg in 1 mL’ with manner of administration Injection:
Solution concentrate for I.V. infusion 20 mg in 1 mL
[67] Schedule 1 Part 1 entry for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 20 mg in 2 mL’ with manner of administration Injection:
[68] Schedule 1 Part 1 after the entry for ‘Docetaxel’ in the form ‘Solution concentrate for I.V. infusion 80 mg in 4 mL’ with manner of administration Injection:
Oncotaxel 80
[69] Schedule 1 Part 1, entry for ‘Doxorubicin’ in the forms ‘Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial’; ‘Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial’; and ‘Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 50 mg in 25 mL single dose vial’ with manner of administration Injection/intravesical:
[70] Schedule 1 Part 1, entry for ‘Epirubicin’ in the forms ‘Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL’; ‘Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL’; ‘Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL’; and ‘Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL’ with manner of administration Injection/intravesical:
[71] Schedule 1 Part 1, entry for ‘Fluorouracil’ in the form ‘Injection 500 mg in 10 mL’ with manner of administration Injection:
C3924
[72] Schedule 1 Part 1, entry for ‘Methotrexate’ in the form ‘Solution concentrate for I.V. infusion 1000 mg in 10 mL vial’ with manner of administration Injection:
[73] Schedule 1, Part 1 after the entry for Mitozantrone;
Solution concentrate for I.V. 100 mg in 5 mL
Solution concentrate for I.V. 1000 mg in 50 mL
[74] Schedule 1 Part 1, entry for ‘Oxaliplatin’ in the forms ‘Powder for I.V. infusion 100 mg’; and ‘Powder for I.V. infusion 50 mg’ with manner of administration Injection:
[75] Schedule 1 Part 1, entry for ‘Paclitaxel’ in the form ‘Solution concentrate for I.V. infusion 100 mg in 16.7 mL’ with manner of administration Injection:
[76] Schedule 1, Part 2 after the entry for Mitozantrone:
P4858
[77] Schedule 2, entry for ‘Folinic Acid’ in the form ‘Injection containing calcium folinate equivalent to 50 mg folinic acid in 5 ml’ with manner of administration Injection:
[78] Schedule 4, after the entry for Methotrexate:
The condition must be CD20 positive chronic lymphocytic leukaemia (CLL), must be previously untreated, and must be in combination with chlorambucil. Patient must be inappropriate for fludarabine based therapy.
The condition must be CD20 positive chronic lymphocytic leukaemia (CLL). The patient must have previously been issued with an authority prescription for this drug, must not have progressive disease, and must be inappropriate for fludarabine based therapy. Treatment must be in combination with chlorambucil.